This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Olumiant
  • /
  • A Study in Moderate to Severe Rheumatoid Arthritis...
Clinical trial

A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM)

Read time: 3 mins
Last updated:1st Oct 2012
Identifier: NCT01710358

The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to methotrexate (MTX) treatment.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Estimated Enrollment: 1280
Study Start Date: October 2012
Estimated Study Completion Date: September 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)

- Placebo Comparator:
- Active Comparator: Adalimumab
- Experimental: Baricitinib

Related journal: Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Category Value
Date last updated at source 2016-05-13
Study type(s) Interventional
Expected enrolment 1307
Study start date 2012-10-01
Estimated primary completion date 2015-09-01

View full details